Scribe Posts Q3 Loss of $9.9M; $174.2M Cash Funds Operations Into 1H 2029
SCTX sits 26% above its 52-week low of $13.5.
Summary
Scribe reported a $9.9 million Q3 net loss and $174.2 million in cash that funds operations into the first half of 2029; STX-1150 Phase 1 data are now expected in 1H 2027.
Key Events · Earnings and Guidance · SCTX
-
Q3 Net Loss Widens to $9.9M
Net loss was $9.9 million, or $0.68 per basic and diluted share, versus $6.5 million in Q2 2026, as G&A rose to $4.2 million from $2.5 million on public-company costs and stock compensation.
-
Cash of $174.2M Funds Into 1H 2029
Cash, cash equivalents and marketable securities stood at $174.2 million at September 30, 2026, up from $43.0 million at June 30, 2026, primarily on roughly $140.2 million of net IPO and concurrent private placement proceeds.
-
Revenue Slips on Lower Lilly Activity
Collaboration revenue was $1.6 million for Q3 2026 versus $1.9 million in Q2 2026, attributed to lower reimbursable R&D under the Eli Lilly collaboration.
-
STX-1150 Phase 1 Data Due 1H 2027
The first-in-human Phase 1 trial of STX-1150 continues enrolling; initial single-ascending-dose safety and LDL-C lowering data are expected in the first half of 2027.
Analysis · SCTX · Life Sciences
The cash pile from the July IPO is the headline here: $174.2 million at September 30 versus $43.0 million at June 30, enough to fund operations into the first half of 2029. That removes any near-term financing need, and the going-concern doubt disclosed for June 30 is now a resolved historical item. The offset is a wider loss — $9.9 million in Q3 versus $6.5 million in Q2 — driven by G&A jumping to $4.2 million from $2.5 million as public-company costs and stock compensation kick in, while collaboration revenue slipped to $1.6 million from $1.9 million on lower Lilly reimbursable activity. On the pipeline, the readout that matters is STX-1150 Phase 1 data, now guided to the first half of 2027, so there is no clinical catalyst in the near term. The Sanofi expansion to include ELXR silencing technology adds a second technology licensed to an existing partner but carries no disclosed new dollar amount.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCTX was trading at $16.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $321.6M. The 52-week trading range was $13.50 to $39.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.